National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
Topics
- Caregiving (1)
- Children/Adolescents (3)
- Data (1)
- Evidence-Based Practice (2)
- Eye Disease and Health (2)
- Family Health and History (1)
- Genetics (1)
- Guidelines (2)
- Healthcare Costs (3)
- Health Status (1)
- Neurological Disorders (1)
- (-) Newborns/Infants (9)
- Patient-Centered Outcomes Research (1)
- Prevention (1)
- Quality of Life (1)
- Research Methodologies (1)
- Respiratory Conditions (1)
- (-) Screening (9)
- Sickle Cell Disease (1)
- Skin Conditions (1)
- U.S. Preventive Services Task Force (USPSTF) (1)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 9 of 9 Research Studies DisplayedOke I, Lutz SM, Hunter DG
Use and costs of instrument-based vision screening for US children aged 12 to 36 months.
This research letter describes a cohort study that examined patterns and out-of-pocket costs of instrument-based vision screening among US children 12 to 36 months. The authors used 2018 MarketScan Commerical Claims and Encounters data as of January 1, 2018 and excluded those with fewer than 12 months of continuous insurance coverage, enrollment in capitated insurance plans, no preventive care encounters, or missing data on residents. The study included 246,077 children. Instrument-based vision screening was received by 19.5% (n = 48,101) of children during 2018. Median (IQR) practitioner payment for instrument-based vision screening claims was $13. Screening incurred out-of-pocket expenses for 7% of children; 30% of these children had expenses related to co-payment, 20.2% to coinsurance, and 50.7% to deductibles. Median (IQR) out-of-pocket expense was $11. Increased odds of vision screening were associated with older age, high-deductible plan enrollment, having more than 1 preventative visit, and receiving care within an area in the highest quartile of practitioner payment. This study was limited by use of commercial claims data, which excluded 45% of children with public or no coverage. Nationwide prevalence of vision screening therefore may differ for the general population.
AHRQ-funded; HS000063.
Citation: Oke I, Lutz SM, Hunter DG .
Use and costs of instrument-based vision screening for US children aged 12 to 36 months.
JAMA Pediatr 2023 Jul; 177(7):728-30. doi: 10.1001/jamapediatrics.2023.0808..
Keywords: Newborns/Infants, Eye Disease and Health, Screening, Prevention, Healthcare Costs
Chen HF, Rose AM, Waisbren S
Newborn screening and treatment of phenylketonuria: projected health outcomes and cost-effectiveness.
This study’s objective was to evaluate the cost-effectiveness of newborn screening and treatment for phenylketonuria (PKU) in the context of new data on adherence to a recommended diet treatment and a newly available drug (sapropterin dihydrochloride). A computer simulation model was developed to project outcomes for a hypothetical cohort of newborns which compared four strategies. The strategies compared were: 1) clinical identification (CI) with diet treatment; 2) newborn screening (NBS) with diet treatment; 3) CI with diet and medication; and 4) NBS with diet and medication. The range of incremental cost-effectiveness ratio went from $6400/QALY for newborn screening with diet treatment compared to clinical identification with diet treatment up to $16,000,000/QALY for adding medication to NBS with diet treatment. Future research is needed to consider conditions under which sapropterin dihydrochloride would be more economically attractive.
AHRQ-funded; HS020644.
Citation: Chen HF, Rose AM, Waisbren S .
Newborn screening and treatment of phenylketonuria: projected health outcomes and cost-effectiveness.
Children 2021 May 12;8(5). doi: 10.3390/children8050381..
Keywords: Newborns/Infants, Neurological Disorders, Screening, Healthcare Costs
Richardson JS, Kemper AR, Grosse SD
Health and economic outcomes of newborn screening for infantile-onset Pompe disease.
The authors sought to estimate health and economic outcomes associated with newborn screening for infantile-onset Pompe disease in the United States. They found that newborn screening for Pompe disease resulted in substantial health gains for individuals with infantile-onset Pompe disease, but with additional costs.
AHRQ-funded; HS020644.
Citation: Richardson JS, Kemper AR, Grosse SD .
Health and economic outcomes of newborn screening for infantile-onset Pompe disease.
Genet Med 2021 Apr;23(4):758-66. doi: 10.1038/s41436-020-01038-0..
Keywords: Newborns/Infants, Screening, Genetics
Abrams EM, Brough HA, Keet C
Pros and cons of pre-emptive screening programmes before peanut introduction in infancy.
In this review, researchers evaluated the advantages and disadvantages of a pre-emptive screening approach before the early introduction of peanuts in infants at high risk of peanut allergy. The Learning Early About Peanut study and the National Institute of Allergy and Infectious Diseases (NIAID) expert panel recommendations are compared.
AHRQ-funded; HS024599.
Citation: Abrams EM, Brough HA, Keet C .
Pros and cons of pre-emptive screening programmes before peanut introduction in infancy.
Lancet Child Adolesc Health 2020 Jul;4(7):526-35. doi: 10.1016/s2352-4642(20)30029-8..
Keywords: Newborns/Infants, Screening, Guidelines, Evidence-Based Practice
Greenhawt M, Shaker M
Determining levers of cost-effectiveness for screening infants at high risk for peanut sensitization before early peanut introduction.
The authors sought to identify scenarios in which current early peanut introduction guidelines would be cost-effective. They found that the current screening approach to early peanut introduction could be cost-effective at a particular health utility for an in-clinic reaction, skin prick test sensitivity and specificity, and high baseline peanut allergy prevalence among high-risk infants. However, such conditions are unlikely to be plausible to achieve realistically. They recommend further research to define the health state utility associated with reaction location.
AHRQ-funded; HS024599.
Citation: Greenhawt M, Shaker M .
Determining levers of cost-effectiveness for screening infants at high risk for peanut sensitization before early peanut introduction.
JAMA Netw Open 2019 Dec 2;2(12):e1918041. doi: 10.1001/jamanetworkopen.2019.18041..
Keywords: Patient-Centered Outcomes Research, Newborns/Infants, Children/Adolescents, Respiratory Conditions, Skin Conditions, Screening, Healthcare Costs, Evidence-Based Practice, Guidelines
Simon NJ, Richardson J, Ahmad A
Health utilities and parental quality of life effects for three rare conditions tested in newborns.
The purposes of this study were to estimate health utilities for three rare, heritable conditions currently recommended for newborn screening - Krabbe disease, phenylketonuria, and Pompe disease - and to estimate the spillover effects experienced by the parents of infants diagnosed with these disorders. A survey elicited health utilities for the three conditions at varying stages and onset of symptoms. Respondents valued disease specific health states in three question frames: adult, child, and parent spillover state. Results reported that more severe conditions and infant health states received lower estimated utility, and estimates of greater disutility among parents.
AHRQ-funded; HS020644.
Citation: Simon NJ, Richardson J, Ahmad A .
Health utilities and parental quality of life effects for three rare conditions tested in newborns.
J Patient Rep Outcomes 2019 Jan 22;3(1):4. doi: 10.1186/s41687-019-0093-6..
Keywords: Caregiving, Family Health and History, Newborns/Infants, Quality of Life, Screening
Jonas DE, Amick HR, Wallace IF
Vision screening in children aged 6 months to 5 years: Evidence report and systematic review for the US Preventive Services Task Force.
The researchers reviewed the evidence on screening for and treatment of amblyopia, its risk factors, and refractive error in children aged 6 months to 5 years to inform the US Preventive Services Task Force. They concluded that studies directly evaluating the effectiveness of screening were limited and do not establish whether vision screening in preschool children is better than no screening.
AHRQ-funded; 290201200015I.
Citation: Jonas DE, Amick HR, Wallace IF .
Vision screening in children aged 6 months to 5 years: Evidence report and systematic review for the US Preventive Services Task Force.
JAMA 2017 Sep 5;318(9):845-58. doi: 10.1001/jama.2017.9900.
.
.
Keywords: U.S. Preventive Services Task Force (USPSTF), Eye Disease and Health, Children/Adolescents, Screening, Newborns/Infants
Hinton CF, Homer CJ, Thompson AA
AHRQ Author: Dougherty D
A framework for assessing outcomes from newborn screening: on the road to measuring its promise.
The researchers proposed a framework for assessing outcomes for the health and well-being of children identified through newborn screening programs. As an example, they applied the framework to sickle cell disease and phenylketonuria, two diverse conditions with different outcome measures and potential sources of data. They concluded that their paper presented a customizable outcomes framework for organizing measures for newborn screening condition-specific health outcomes, and an approach to identifying sources and challenges to populating those measures.
AHRQ-authored.
Citation: Hinton CF, Homer CJ, Thompson AA .
A framework for assessing outcomes from newborn screening: on the road to measuring its promise.
Mol Genet Metab 2016 Aug;118(4):221-9. doi: 10.1016/j.ymgme.2016.05.017.
.
.
Keywords: Children/Adolescents, Health Status, Newborns/Infants, Screening, Sickle Cell Disease
Thiel DB, Platt J, Platt T
Testing an online, dynamic consent portal for large population biobank research.
Michigan's BioTrust for Health contains over 4 million samples collected without written consent. Participant-centric initiatives are IT tools that hold great promise to address the consent challenges in biobank research. The authors created and pilot tested a dynamic informed consent simulation focusing on consent for research. Pilot testers raised concerns about the process of identity verification and appeared to have little experience with sharing health information online. The authors recommended applying online, dynamic approaches to address the consent challenges raised by biobanks with legacy sample collections.
AHRQ-funded; HS000053.
Citation: Thiel DB, Platt J, Platt T .
Testing an online, dynamic consent portal for large population biobank research.
Public Health Genomics 2015;18(1):26-39. doi: 10.1159/000366128.
.
.
Keywords: Data, Newborns/Infants, Research Methodologies, Screening